Christopher Lucci, MD
Public Health & General Preventive Medicine · Rockport, TXNPI 1447241955
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $694,864 of the $900,829 with a category attached, or 77.1%. 37 manufacturers reported payments, led by Novo Nordisk at 49.4% of the total. Among public health & general preventive medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,098 payments — averaging $820.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$445K
- Corcept Therapeutics$315K
- Johnson & Johnson$120K
- Esperion Therapeutics, Inc.$9K
- AstraZeneca$8K
- Mannkind Corporation$655
- plus $3K from 31 others
What the payments were for
- Consulting fees$31,3503%
- Speaking & faculty fees$694,86477%
- Travel & lodging$154,51017%
- Food & beverage$19,9552%
- Education$1500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 452 | $444,810 |
| Corcept Therapeutics | 308 | $315,469 |
| Johnson & Johnson | 158 | $119,576 |
| Esperion Therapeutics, Inc. | 18 | $9,103 |
| AstraZeneca(2 entities) | 22 | $8,198 |
| Mannkind Corporation | 18 | $655 |
| Bayer | 28 | $521 |
| Xeris Pharmaceuticals, Inc. | 10 | $308 |
| Lilly USA, LLC | 12 | $267 |
| GSK | 2 | $200 |
| Tandem Diabetes Care, Inc. | 2 | $198 |
| Medtronic | 1 | $190 |
| Amgen | 9 | $178 |
| Novartis | 8 | $175 |
| Dexcom, Inc. | 6 | $128 |
| Recordati_rare_diseases_inc. | 4 | $124 |
| Arbor Pharmaceuticals, Inc. | 8 | $122 |
| Antares Pharma, Inc. | 4 | $78 |
| Amarin Pharma, Inc. | 3 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $54 |
| Abbott | 2 | $48 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| Nevro Corp. | 2 | $36 |
| Tactile Systems Technology Inc | 1 | $31 |
| BETA Bionics, Inc. | 2 | $27 |
| Aytu Biopharma, Inc. | 2 | $26 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
| Tolmar, Inc. | 1 | $22 |
| AbbVie | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Radius Health, Inc. | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Sequel Med Tech, LLC | 1 | $15 |
| Astellas Pharma US Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$900,829 in reported general payments places this provider in the 95th percentile of 41 public health & general preventive medicine providers in Texas.
See all public health & general preventive medicine providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 80 | $3,766,516 |
| RecorlevLevoketoconazole | 21 | $762,808 |
| OzempicSemaglutide | 408 | $422,809 |
| MounjaroTirzepatide | 136 | $137,894 |
| KerendiaFinerenone | 116 | $83,274 |
| FarxigaDapagliflozin Propanediol | 102 | $82,088 |
| XareltoRivaroxaban | 108 | $81,853 |
| RybelsusSemaglutide | 76 | $80,161 |
| ForteoTeriparatide | 12 | $58,480 |
| Xigduo XrDapaglifloz Propaned/Metformin | 52 | $42,932 |
| JardianceEmpagliflozin | 37 | $33,893 |
| InvokanaCanagliflozin | 39 | $30,728 |
| Repatha SureclickEvolocumab | 40 | $26,155 |
| VascepaIcosapent Ethyl | 52 | $25,643 |
| NexlizetBempedoic Acid/Ezetimibe | 35 | $21,151 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $315,469 | $3,766,51680 claims |
| Xeris Pharmaceuticals, Inc.Recorlev | $308 | $762,80821 claims |
| Novo NordiskOzempic, Rybelsus | $444,810 | $502,970484 claims |
| Lilly USA, LLCMounjaro, Forteo | $267 | $196,374148 claims |
| Johnson & JohnsonXarelto, Invokana | $119,576 | $112,581147 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $8,198 | $92,682119 claims |
| BayerKerendia | $521 | $83,274116 claims |
| Esperion Therapeutics, Inc.Nexlizet | $9,103 | $21,15135 claims |
| AmgenProlia | $178 | $18,97612 claims |
| NovartisEntresto | $175 | $14,72623 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $54 | $13,50430 claims |
| Astellas Pharma US IncMyrbetriq | $12 | $13,04925 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 41 public health & general preventive medicine providers in Texas.
Other public health & general preventive medicine in Rockport
- James SheehanFort Sam Houston$287K
- Barry DavisHouston$57K
- Richard LeconeyAlvin$24K
- Tyler CooperDallas$2K
- Prathima NagireddyFort Worth$2K
- John CarloDallas$1K
- Olivia IvyAustin$685
- Ryan GottfredsonJbsa Lackland$490
- Steven ClarkDallas$476
- Joseph CleaverDallas$331
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.